Jennifer Adgey - Concepedia

Author

Jennifer Adgey

Also Known As

Adgey, Jennifer, J ADGEY, J. A. Adgey, JENNIFER A.A. ADGEY, JENNIFER AA. ADGEY, Jennifer A Adgey, Jennifer A. Adgey, Jennifer A.A Adgey, Jennifer Adgey, Jennifer Adgey (UK)

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

University of Ulster Royal Victoria Hospital University of Alberta Royal Victoria Eye and Ear Hospital Craigavon Area Hospital

About

Jennifer Adgey is an author at University of Ulster specializing in medicine, cardiology, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	437
2	Public Health	5	5	149
3	Engineering	1	1	30
4	Health Sciences	1	1	19
5	Applied Physiology	1	1	19

Jennifer Adgey

Publications

Citations

H-Index

Page 1

	Year	Citations
Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T Levels Christian W. Hamm, Christopher Heeschen, Britta Goldmann, New England Journal of Medicine	1999	710
Thrombolysis during Resuscitation for Out-of-Hospital Cardiac Arrest Bernd W. Böttiger, Hans-Richard Arntz, Douglas Chamberlain, New England Journal of Medicine	2008	398
Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T Conor McCann, Ben Glover, Ian Menown, European Heart Journal	2008	233
Evaluation of a Weight-Adjusted Single-Bolus Plasminogen Activator in Patients With Myocardial Infarction Peter den Heijer, Frank Vermeer, Ettore Ambrosioni, Circulation	1998	97
Prognostic Value of a Multimarker Approach for Patients Presenting to Hospital With Acute Chest Pain Conor McCann, Ben Glover, Ian Menown, The American Journal of Cardiology Prognostic EvaluationHeart FailurePrognostic ValuePatient SafetyDiagnosis	2008	89
Randomized, Double-Blind Study Comparing Saruplase With Streptokinase Therapy in Acute Myocardial Infarction: The COMPASS Equivalence Trial fn1fn1This study was supported by Grünenthal GmbH, the manufacturer of saruplase. Ulrich Tebbe, Rolf Michels, Jennifer Adgey, Journal of the American College of Cardiology ThrombosisCardiovascular DiseaseMedicineClinical TrialsCardiovascular Pharmacology	1998	89
Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK) Anil Taneja, J Collinson, Marcus Flather, European Heart Journal	2004	45
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the assessment of the safety of a new thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction Peter Sinnaeve, John H. Alexander, Kris Bogaerts, American Heart Journal ThrombosisCardiovascular DiseaseAtherosclerosisMedicineUnfractionated Heparin	2004	45
Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: Findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS Peter Sinnaeve, Yao Huang, Kris Bogaerts, American Heart Journal ThrombosisVenous ThrombosisCardiovascular DiseaseIschemic StrokeMedicine	2006	40
Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial Freek W.A. Verheugt, Gilles Montalescot, Marc S. Sabatine, Journal of Thrombosis and Thrombolysis ThrombosisDual Antiplatelet TherapyCardiovascular DiseaseFibrinolysisClarity-timi 28	2006	35

Page 1